Company profile
Geron Corporation
NASDAQ: GERN · Healthcare · Biotechnology
#992 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
50DFH 35DQ 79GM 24SS 82
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$196.1M
Rev growth YoY (TTM)
+68.6%
Net income (FY)
-$83.5M
Employees
258
as of 2026-08-10
Market cap
$949.5M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$237.0k$237.0k2023
Net income-$83.5M-$83.5M2025
Operating income-$68.6M-$68.6M2025
Total assets$570.5M$570.5M2025
Liabilities$344.7M$344.7M2025
Equity$225.9M$225.9M2025
Revenue trend
FY2019 – FY2023 · USD
FY19
FY19
FY19
FY19
FY20
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2025
By product
Revenues Before Adjustments67%
Product55%
Government Rebates-1%
Sales Returns And Allowance-1%
Chargebacks-8%
Total Gross To Net Adjustments-12%
By geography
Not disclosed.
The read
What is Geron Corporation’s revenue?
Geron Corporation booked $237.0k in FY2023 revenue, contracting 60% year over year — slower than 84% of Healthcare companies we track, at a -35232.1% net margin.
Peers · Healthcare
Wellness Center USA, Inc.——LiveWire Ergogenics, Inc.——Sproutly Canada Inc.——Regen BioPharma, Inc.35DBlueberries Medical Corp.32DFamily Office of America Inc.37DNeighbors
San Mateo →Key facts
CEOHarout Semerjian
SectorHealthcare
IndustryBiotechnology
HeadquartersFoster City, CA
ExchangeNASDAQ: GERN
Employees258
IPO date1996-07-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.